Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
AstraZeneca
Hoffmann-La Roche
Amgen
Daiichi Sankyo
Bayer
Bristol-Myers Squibb
Mirati Therapeutics Inc.
Merck Sharp & Dohme LLC
Pfizer
Hoffmann-La Roche
Hutchmed
Seagen Inc.
Merck Sharp & Dohme LLC
Taiho Oncology, Inc.
Pfizer
Hutchmed